Genome-Wide Association Study of Treatment Refractory Schizophrenia in Han Chinese

Ying-Jay Liou1,2,*, Hui-Hung Wang3,*, Ming-Ta Michael Lee3,4,*, Sheng-Chang Wang5,*, Hung-Lun Chiang2,3, Cheng-Chung Chen6, Ching-Hua Lin6, Ming-Shun Chung7, Chien-Cheng Kuo7, Ding-Lieh Liao8, Ching-Kuan Wu9, Chih-Min Liu10, Yu-Li Liu5, Hai-Gwo Hwu10,11, I-Ching Lai12, Shih-Jen Tsai1,13, Chia-Hsiang Chen5, Hui-Fen Liu3, Yi-Chun Chou3, Chien-Hsiun Chen3,4, Yuan-Tsong Chen3,14, Chen-Jee Hong1,13,15,*, Jer-Yuarn Wu4,*,

1 Department of Psychiatry, Taipei Veterans General Hospital, Taipei, Taiwan, 2 Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan, 3 Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan, 4 School of Chinese Medicine, China Medical University, Taichung, Taiwan, 5 Division of Mental Health and Addiction Medicine, Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan, 6 Kaohsiung Kai-Suan Psychiatric Hospital, Kaohsiung, Taiwan, 7 Jianan Mental Hospital, Department of Health, Executive Yuan, Taiwan, 8 Bali Psychiatric Center, Department of Health, Executive Yuan, Taiwan, 9 Tsyr-Huey Mental Hospital, Kaohsiung, Taiwan, 10 Department of Psychiatry, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, 11 Department of Psychology, College of Science, National Taiwan University, Taipei, Taiwan, 12 Yuli Veterans Hospital, Hualien, Taiwan, 13 Department of Medicine, National Yang-Ming University, Taipei, Taiwan, 14 Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, United States of America, 15 Institute of Brain Science, National Yang-Ming University, Taipei, Taiwan

Abstract

We report the first genome-wide association study of a joint analysis using 795 Han Chinese individuals with treatment-refractory schizophrenia (TRS) and 806 controls. Three loci showed suggestive significant association with TRS were identified. These loci include: rs10218843 (P = 3.04 x 10^-8) and rs11265461 (P = 1.94 x 10^-7) are adjacent to signaling lymphocytic activation molecule family member 1 (SLAMF1); rs4699030 (P = 1.94 x 10^-6) and rs230529 (P = 1.74 x 10^-7) are located in the gene nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (NFKB1); and rs13049286 (P = 3.05 x 10^-5) and rs3827219 (P = 1.66 x 10^-5) fall in receptor-interacting serine/threonine-protein kinase 4 (RIPK4). One isolated single nucleotide polymorphism (SNP), rs739617 (P = 3.87 x 10^-5) was also identified to be associated with TRS. The -94delATTG allele (rs28362691) located in the promoter region of NFKB1 was identified by resequencing and was found to associate with TRS (P = 4.85 x 10^-6). The promoter assay demonstrated that the -94insATTG allele had a significant lower promoter activity than the -94insATTG allele in the SH-SYSY cells. This study suggests that rs28362691 in NFKB1 might be involved in the development of TRS.

Introduction

Schizophrenia is a severe psychiatric disorder with a prevalence estimated to be approximately 1% [1] in the world and 0.6% in Taiwan [2]. It is the third-leading cause of disability among individuals age between 15 and 44 [3]. Its clinical manifestations are characterized by distortion of reality, delusions, hallucinations, altered emotional reactivity, disorganized behavior, social isolation and cognitive impairment. The etiology of schizophrenia is not well understood but it has been postulated as a complex disease with an estimated heritability as high as 80% [4] [5].

Genetic studies based on linkage and positional candidate genes approaches have suggested multiple candidate molecules in the pathogenesis of schizophrenia, including the receptors of antipsychotics [DRD2] [6], HTR2A [7], CHRNA7 [8], TAIR6 [9]; the enzymes affecting neurotransmitter metabolisms [COMT] [10], DA04 [11]; factors involved in microtubules function [DISC1 [12]]; neuronal differentiation [NRG1 [13]]; signal transduction [RGS4 [14]]; and calmodulin-dependent protein phosphatase (PP5CC [15]). However, most of these genes lack of replicable support across populations [16,17].

Genome-wide association study (GWAS) is a hypothesis-free approach to comprehensively identify disease susceptibility loci. It has identified several susceptible genetic variants associated with schizophrenia, such as SNPs located on or near genes involved in transcriptional regulations (ZNF804A [18,19] and ZNF814 [20]); neuronal functioning (NRGN [21], and ANK3 [22]); cytokine activities (CSP2RA [23] and IL3RA [24]), inflammatory responses (PLA2 [25]), immune function (MHCC region [20,21,24] and TCF4 [21]); brain development (PGRIPF1 [18], PLXNA2 [25], RELN [26]); endocrine functioning (ACS/M1 [22]); and chromatin remodeling (SMA/RCA2 [27]). However, these studies have not replicated the candidate genes or linkage studies in schizophrenia and most of the findings from GWAS are still inconsistent. The discordant

Citation: Liou Y-J, Wang H-H, Lee M-TM, Wang S-C, Chiang H-L, et al. (2012) Genome-Wide Association Study of Treatment Refractory Schizophrenia in Han Chinese. PLoS ONE 7(3): e33598. doi:10.1371/journal.pone.0033598

Editor: Xiang Yang Zhang, Baylor College of Medicine, United States of America

Received: October 10, 2011; Accepted: February 13, 2012; Published: March 27, 2012

Copyright: © 2012 Liou et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was supported by the National Research Program for Genomic Medicine, National Science Council, Taiwan (NSC-99-1112-B-001-022 NSC-99-3112-B-001-023). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: jywu@ibms.sinica.edu.tw (JYW); cjhong@vghtpe.gov.tw (CJH)
9 These authors contributed equally to this work.
results were likely due to the phenotypic variability associated with schizophrenia since schizophrenia is a heterogeneous disorder as well as the lack of statistical power due to find common variants of susceptibility.

Antipsychotic medication is the major treatment for schizophrenia. However, one fifth to one third of schizophrenic patients do not respond to antipsychotic treatments [28,29]. These patients with treatment refractory schizophrenia (TRS) have persistent psychotic symptoms combining with poor social/work function in spite of administering at least two trials of sufficient antipsychotic doses and adequate treatment duration [28]. Comparing with those patients with adequate responses to antipsychotic treatments, patients with TRS had significantly lower levels of catecholamine in cerebrospinal fluid or plasma [30], increased cortical atrophy [31,32], and a lower level of plasma tryptophan concentrations [33]. Therefore, TRS may be a distinct and homogenous subgroup of schizophrenia.

To identify the genetic variants susceptible for schizophrenia, this study performed the first GWAS focusing on TRS in a Han-Chinese population. We identified several novel genetic loci which were not associated with schizophrenia. Our findings may pave a new way to elucidate the underlying molecular mechanism of schizophrenia and to improve the treatment for TRS.

Results

Demographic information

Demographic data from 522 TRS patients and 806 controls is listed in Table 1. The mean age was 44.12 ± 9.06 years in cases and 67.64 ± 9.36 years in controls. The male made up approximately 55% in cases and 48% in controls. Of these patients, 121 patients (23.2%) had a family history of psychiatric disorders; 264 patients (50.6%) displayed psychotic symptoms before age 20; 289 patients (55.4%) had shown violent or homicidal behavior; and 197 patients (37.7%) had attempted suicide. All of the patients showed persistence of their illness for more than 5 years, with a persistent CGI-S score of 4 or higher under antipsychotic treatments.

Data quality

The average call rate was 99.8 ± 0.3% for each subject genotyped in this study. Gender determined from the GWAS result for all the subjects was consistent with recorded data. 694,436 (79.99%) of the 868,114 SNP in the autosomes passed the quality control filter and had an average call rate of 99.8% (Supplementary Table S1). The results of principal component analysis showed no significance for population stratification between TRS patients and controls, (P > 0.05, and Fst statistics between populations <0.001) (Supplementary Figure S1). Furthermore, genomic control with a variance inflation factor λ = 1.042 (trend test), estimated posterior to the regular GWAS, also indicated no substantial population stratification. These SNPs were then taken for further GWAS analysis.

Association analysis

Data analysis was first performed for the 522 TRS patients and 806 controls (Figure 1). Preliminary results revealed 19 SNPs with suggestive significant associations with TRS (Supplementary Table S2, 10^{-4} < P < 10^{-3}). Fourteen markers were retained after cross platform validation with the Sequenom platform and showed a concordance rate of over 98% (Supplementary Table S2).

Four major clusters with more than one SNPs located within 500 kb of each other were identified from the 14 validated SNPs (Table 2, Figure 2). The first locus, comprising rs10218643 (P = 6.73 × 10^{-6}) and rs11265461 (P = 5.90 × 10^{-6}), is located approximately 10 kb downstream of signaling lymphocytic activation molecule family member 1 (SLAMF1) on chromosome 1; the second locus contains two SNPs, rs4699030 (P = 8.41 × 10^{-7}) and rs230529 (P = 1.07 × 10^{-5}), is located in the introns of nuclear factor kappa light polypeptide gene enhancer in B-cells 1 (NFkB1) on chromosome 4; three SNPs, rs379617 (P = 1.46 × 10^{-6}), rs17158926 (P = 3.99 × 10^{-7}) and rs17158930 (P = 3.08 × 10^{-7}) are clustered in the introns of dedicator of cytokinesis 4 (DOCK4) on chromosome 7; and the last locus which consists of two SNPs, rs13049289 (P = 1.23 × 10^{-5}) and rs3027219 (P = 1.23 × 10^{-5}), is located in receptor-interacting serine/threonine-protein kinase 4 (RIPK4) on chromosome 21. These loci are located in the regions with high LD (except for chromosome 21) (Supplementary Figure S2). Multi-point/Haplotype analysis also showed that these clusters were associated with TRS, the cluster on chromosome 4 had the highest P value with global score P = 2 × 10^{-8} (Supplementary Table S3).

In addition to the above SNPs in clusters, five other SNPs also showed suggestive significant association with TRS. These SNPs are: rs461409 (P = 2.63 × 10^{-5}) which is located 175 kb downstream of RGM domain family, member B (RGMb) on chromosome 5; rs123533497 (P = 1.04 × 10^{-5}) in intron 14 of A-kinase anchor protein 9 (AKAP9) on chromosome 7; rs9314462 (P = 5.30 × 10^{-5}) in the downstream of CUB and sushi domain-containing protein 1 (CUBN) on chromosome 8; rs9646303 (P = 1.15 × 10^{-5}) in intron 3 of zinc finger, CCHC domain containing 14 (ZCCHC14) on chromosome 16; and rs11673496

| Characteristics | Patients with TRS (N = 522) | Controls (N = 806) |
|-----------------|----------------------------|------------------|
| Male (%)        | 289 (55.4%)                | 383 (47.5%)      |
| Age- years      | 44.12                      | 67.64            |
| Body-mass index | 24.74                      | 24.25            |
| smoking - no. (%) | 225 (43.1%)             | 270 (33.5%)      |
| regular drinker - no. (%) | 44 (8.4%)       | 90 (11.2%)       |
| Family history of psychiatric disease | 121 (23.2%) | 33 (4.09%) |
| onset before 20 yr | 264 (50.6%)            | -                |
| violent or homicidal - no. (%) | 289 (55.4%)       | -                |
| suicide attempt - no. (%) | 197 (37.7%)       | -                |
| Recruitment for TRS - no. (%) | - | - |
| two trials of standard antipsychotic treatments | 90 (17.24%) | - |
| clozapine | 432 (82.76%) | - |
| Severity of TRS : scale of CGI-S | | |
| 1. normal | 0 | - |
| 2. borderline mentally ill | 0 | - |
| 3. mildly ill | 0 | - |
| 4. moderately ill | 129 (24.7%) | - |
| 5. markedly ill | 265 (50.8%) | - |
| 6. severely ill | 115 (22.0%) | - |
| 7. extremely ill | 13 (2.5%) | - |

# means the body-mass index is the weight in kilograms divided by the square of the height in meters. 

* means more than 5 years of persistence of illness without period of good social or occupational functioning assessed by the severity of illness subscale of clinical global impression (CGI-S).
Figure 1. Graphical summary of genome-wide association analysis for TRS in a Han Chinese population. Results ($-\log_{10}(p)$) are shown in chromosomal order for 694,436 SNPs which were tested in 522 cases and 806 controls by using Affymetrix SNP 6.0 Array. The horizontal line indicates a $p$-value of $10^{-5}$.

doi:10.1371/journal.pone.0033598.g001

Table 2. Results of GWAS for TRS in Han population.

| ch | SNP position | Allele | RA in control | RA in case | F difference | $P_{\text{trend}}$ | OR (95% CI) | $P_{\text{joint}}$ | OR joint (95% CI) | closest gene | Distance to gene (bp) |
|----|--------------|--------|---------------|------------|--------------|----------------|--------------|----------------|---------------------|-------------|----------------------|
| 1  | rs10218843   | 158892685 CT C | 0.407 | 0.495 | 0.088 | 6.73 x 10$^{-6}$ | 1.43 (1.22-1.67) | 3.04 x 10$^{-7}$ | 1.45 (1.26-1.66) | SLAMF1 | 8980 |
| 1  | rs11265461   | 158896767 CT C | 0.411 | 0.500 | 0.089 | 5.90 x 10$^{-6}$ | 1.43 (1.22-1.68) | 4.33 x 10$^{-7}$ | 1.45 (1.26-1.67) | SLAMF1 | 13062 |
| 4  | rs230529     | 103676448 CT C | 0.472 | 0.570 | 0.097 | 1.07 x 10$^{-6}$ | 1.48 (1.27-1.73) | 1.74 x 10$^{-7}$ | 1.45 (1.26-1.66) | NFKB1 | 0 |
| 4  | rs4699030    | 103722862 CG C | 0.470 | 0.568 | 0.098 | 8.41 x 10$^{-7}$ | 1.48 (1.27-1.73) | 3.65 x 10$^{-6}$ | 1.40 (1.22-1.61) | NFKB1 | 0 |
| 5  | rs461409     | 97957866 AG G | 0.793 | 0.864 | 0.071 | 3.01 x 10$^{-6}$ | 1.65 (1.33-2.05) | 4.50 x 10$^{-6}$ | 1.39 (1.15-1.66) | RMGB | -175034 |
| 5  | rs12533497   | 91495608 CT T | 0.071 | 0.122 | 0.051 | 1.04 x 10$^{-5}$ | 1.81 (1.39-2.36) | 1.69 x 10$^{-5}$ | 1.60 (1.25-2.05) | AKAP9 | 0 |
| 7  | rs739617     | 111298102 AG A | 0.130 | 0.191 | 0.061 | 1.46 x 10$^{-5}$ | 1.58 (1.28-1.95) | 3.87 x 10$^{-5}$ | 1.50 (1.23-1.82) | DOCK4 | 0 |
| 7  | rs17158926   | 111298199 AT A | 0.135 | 0.193 | 0.059 | 3.99 x 10$^{-5}$ | 1.54 (1.25-1.90) | 5.08 x 10$^{-5}$ | 1.40 (1.16-1.70) | DOCK4 | 0 |
| 7  | rs17158930   | 111298374 AG G | 0.134 | 0.193 | 0.059 | 3.08 x 10$^{-5}$ | 1.55 (1.26-1.91) | 3.98 x 10$^{-5}$ | 1.41 (1.17-1.71) | DOCK4 | 0 |
| 8  | rs9314462    | 2501291 CT C | 0.199 | 0.266 | 0.066 | 5.30 x 10$^{-5}$ | 1.45 (1.21-1.75) | 5.35 x 10$^{-5}$ | 1.34 (1.13-1.59) | CSM1 | -278992 |
| 16 | rs9646303    | 86019470 CT C | 0.409 | 0.496 | 0.087 | 1.15 x 10$^{-5}$ | 1.42 (1.22-1.67) | 3.33 x 10$^{-5}$ | 1.30 (1.13-1.49) | ZCC1C14 | 0 |
| 19 | rs11673496   | 22581270 AG G | 0.732 | 0.807 | 0.075 | 1.75 x 10$^{-5}$ | 1.53 (1.27-1.85) | 2.24 x 10$^{-5}$ | 1.37 (1.16-1.61) | ZNF692 | -60996 |
| 21 | rs13049267   | 42049868 AC C | 0.014 | 0.041 | 0.027 | 1.23 x 10$^{-5}$ | 3.08 (1.83-5.18) | 3.05 x 10$^{-5}$ | 2.78 (1.70-4.56) | RIPK4 | 0 |
| 21 | rs3827219    | 42053555 AG A | 0.014 | 0.042 | 0.028 | 1.23 x 10$^{-5}$ | 3.02 (1.81-5.03) | 1.66 x 10$^{-5}$ | 2.80 (1.73-4.55) | RIPK4 | 0 |

SNP position were indexed to the forward of NCBI Build 36.3.
ch: chromosome.
RA: Risk allele, the allele with higher frequency in schizophrenia as compared with controls; RA: risk allele frequency.
F: frequency.
$P_{\text{trend}}$: $p$ values obtained from the initial GWA analysis on 522 cases and 806 controls.
$P_{\text{joint}}$: $p$ values calculated from joint analysis on 804 cases and 806 controls.
OR, odds ratio for risk allele.
doi:10.1371/journal.pone.0033598.t002
(P = 1.75 \times 10^{-5}), 60 \text{ kb upstream of zinc finger protein 492 (ZNF492) on chromosome 19 (Table 2, Supplementary Figure S3). Except for rs13049286 and rs3827219 with odds ratio (OR) of approximately 3, all other SNPs identified in this study showed modest effects with OR between 1.06–1.81 (Table 2).

Joint Analysis in with additional TRS patients

The 14 SNPs showing suggestive significance were then genotyped in an independent cohort of 273 TRS patients. An average call rate of 99.37\% was achieved for each subject. Joint analysis was then carried out in the 795 cases and 806 controls. Of the 14 SNPs showing suggestive association in the initial analysis, 7SNPs remain suggestively associated with TRS after joint analysis (Table 2). These SNPs are: rs10218843 (P_{joint} = 3.04 \times 10^{-7}) and rs11265461 (P_{joint} = 1.94 \times 10^{-7}) which both are located in SLAMF1; rs230529 (P_{joint} = 1.47 \times 10^{-7}) and rs4699030 (P_{joint} = 1.94 \times 10^{-7}) are located in NFKB1; rs739617 (P_{joint} = 3.87 \times 10^{-7}) is in DOCK4; rs13049268 (P_{joint} = 3.05 \times 10^{-7}) and rs3827219 (P_{joint} = 1.66 \times 10^{-7}) which are located in RIPK4.

Testing in schizophrenic patients

The top SNPs showing suggestive significance were then tested in an independent cohort of 1982 schizophrenic patients whose responses to antipsychotic treatments were not determined and additional 2000 controls. An average call rate of 99.37\% was achieved for each subject. However, none of these SNPs were significantly associated with this group of patients (Supplementary Table S4), suggesting that these SNPs were specifically associated with TRS and not a broad phenotype of schizophrenia.

Re-sequencing of NFKB1

Because the lowest P values in both single and multi-point analysis were observed for the SNPs located on NFKB1 on chromosome 4, we next aimed to identify variants with functional consequence in NFKB1. Re-sequencing was performed on the exons, intron-exon boundaries, and a 2-kb region covering the promoter of NFKB1 in a discovery cohort of 94 TRS patients and 94 controls. Twenty-three genetic polymorphisms including 11 novel variants and 2 non-synonymous changes (R231L and R534H) were identified in NFKB1 (Table 3). The rs28362491 SNP with an ATTG deletion in the promoter region of NFKB1 (94delATTG) was reported to affect nuclear protein binding and gene transcription in colonic epithelial cells [34]. In a test with 520 TRS cases and 806 controls, rs28362491 was associated with TRS (P = 6.69 \times 10^{-5}). rs28362491 is in linkage disequilibrium with rs230529 and rs4699030 (r^2 = 0.741 and 0.714, respectively) (Figure 3).

Functional analysis of rs28362491

Since rs28362491 has been reported to affect nuclear protein binding and gene transcription in colonic epithelial cells, it is possible that the deletion also alters the efficiency of transcription in neuronal cells. The promoter assay showed that the construct containing the -94delATTG promoter displayed significantly
Table 3. Variants identified in NFKB1 by direct sequencing in 94 TRS cases and controls.

| SNP       | Region | Allele | Genotype       | case (%) | control (%) | Effect | Risk Allele | RAF      | F difference |
|-----------|--------|--------|----------------|----------|-------------|--------|-------------|----------|--------------|
| rs28362491| P      | ATG/-  | ins/ins/ins/-/  | 24.4 : 46.7 : 28.9 | 31.7 : 47.8 : 20.5 | del    | 0.522      | 0.444 0.078 |
| rs11940017| T      | T>C    | TT:TC:CC       | 85.9 : 141 : 0   | 95.7 : 43 : 0   | C      | 0.071      | 0.022 0.049 |
| rs11944443| p      | A>G    | AA:AG:GG       | 85.9 : 141 : 0   | 95.7 : 43 : 0   | G      | 0.071      | 0.022 0.049 |
| rs41477752| I2     | T>A    | TT:T/T/-/-     | 87.0 : 130 : 0   | 95.6 : 44 : 0   | del    | 0.065      | 0.022 0.043 |
| IVS2-60  | A>G    | I2     | AA:AG:GG       | 98.9 : 1 : 0     | 100.0 : 0 : 0   | G      | 0.005      | 0 0.005   |
| rs11944443| p      | A>G    | AA:AG:GG       | 98.9 : 1 : 0     | 100.0 : 0 : 0   | G      | 0.005      | 0 0.005   |
| rs4648049 | I2     | C>T    | CC:CT:TT       | 86.2 : 13 : 0    | 95.5 : 45 : 0   | T      | 0.069      | 0.022 0.047 |
| rs4648050 | I2     | T>C    | TT:TC:CC       | 25.5 : 36 : 2 : 38.3 | 27.0 : 49.4 : 23.6 | C    | 0.564      | 0.483 0.081 |
| rs52+21   | C>T    | I2     | CC:CT:TT       | 98.9 : 1 : 0     | 100.0 : 0 : 0   | T      | 0.005      | 0 0.005   |
| rs1020760 | I1     | G>C    | GG:GC:CC       | 42.1 : 40 : 0 : 17.9 | 24.7 : 50.6 : 24.7 | G    | 0.621      | 0.5 0.121 |
| IVS11-56  | T>C    | I1     | TT:TC:CC       | 97.9 : 2 : 1 : 0  | 98.9 : 1 : 1 : 0 | C      | 0.011      | 0.006 0.005 |
| rs1161    | G>A    | E1     | GG:Ga:AA       | 98.9 : 1 : 0     | 100.0 : 0 : 0   | 372S   | A          | 0.005 0.005 |
| IVS1+196  | T>G    | I3     | TT:TG:GG       | 98.9 : 1 : 0     | 100.0 : 0 : 0   | G      | 0.005      | 0 0.005   |
| rs1601    | G>A    | E1     | GG:Ga:AA       | 98.9 : 1 : 0     | 100.0 : 0 : 0   | R534H  | A          | 0.005 0.005 |
| rs51+12   | C>G    | I5     | CC:CG:GG       | 98.9 : 1 : 0     | 100.0 : 0 : 0   | G      | 0.005      | 0 0.005   |
| rs55+40   | G>A    | I5     | GG:Ga:AA       | 98.9 : 1 : 0     | 100.0 : 0 : 0   | A      | 0.005      | 0 0.005   |
| rs4648095 | I7     | T>C    | TT:TC:CC       | 81.1 : 18.9 : 0  | 93.6 : 96 : 0   | C      | 0.095      | 0.032 0.063 |
| rs4648110 | I2     | T>A    | TT:T/A:AA      | 92.6 : 7.4 : 0   | 87.1 : 12.9 : 0 | T      | 0.963      | 0.935 0.028 |
| rs4648117 | I2     | C>T    | CC:CT:TT       | 80.6 : 19.4 : 0  | 94.3 : 5.7 : 0  | T      | 0.097      | 0.028 0.069 |
| IVS2-23   | C>T    | I2     | CC:CT:TT       | 97.8 : 2.2 : 0   | 100.0 : 0 : 0   | T      | 0.011      | 0 0.011   |
| rs3817685 | G>C    | I2     | GG:GC:CC       | 32.6 : 41.3 : 26.1 | 20.5 : 52.3 : 27.3 | G    | 0.533      | 0.466 0.067 |
| rs35795162| G>A    | I3     | -/-/-:AA       | 77.4 : 20.4 : 2.2 | 90.9 : 9.1 : 0  | A      | 0.124      | 0.045 0.079 |
| rs52+34   | G>A    | I3     | GG:Ga:AA       | 98.9 : 1 : 0     | 100.0 : 0 : 0   | A      | 0.005      | 0 0.005   |

Risk allele means the allele with higher frequency in schizophrenia as compared with controls;
RAF: risk allele frequency.
P: promoter, I: intron.
doi:10.1371/journal.pone.0033598.t003

Discussion

This study presented the data of the first GWAS on TRS in a Han-Chinese population. Therefore, the use of genomic control did not substantially change the results of this GWAS (Supplementary Table S5). The sample size is comparatively smaller than in previous GWAS for schizophrenia due to the smaller number of TRS patients available. Since schizophrenia is an etiologically heterogeneous disorder, narrowing schizophrenia down to TRS may represent a more discrete and genetically homogeneous group to identify genes involved in the etiology of schizophrenia.

Among the genetic loci with suggestive significance identified by this study, three regions with more than one significant SNP in each region stood out after joint analysis. rs4699030 and rs230529 are located in the introns of NFKB1. This gene encodes for two functional different proteins [35], one for the 105 kD (p105) protein, and the other for a 50 kD (p50) protein. P105 contains seven copies of ankyrin-like sequence in the carboxyl terminal region which is similar to those in I-kappa B kinase (IkB), therefore, p105 may also have functions similar to IkB. P105 could associate with either c-Rel or RelA in the cytoplasm to inhibit Rel protein-specific transcription [36,37]. P50 is one subunit of NF-kappa B with repression activity. NF-kappa B is well distributed and a highly conserved dimeric transcriptional factor which regulates more than 200 genes [38]. Different dimeric combinations of NF-kappa B are found in different tissues and respond differently to regulate gene expressions. P50 assembles either with other NF-kappa B subunits, such as RelA, RelB, c-Rel, or with itself as a homodimer to repress NF-kappa B-dependent gene transcriptions [39]. The heterodimer of p30 and RelA subunit is the most abundant form of NF-kappa B [40].

Both rs10218843 and rs11263461 are located near SLAMF1 (also known as CD150), which is a signaling lymphocyte activation molecule and a member of the CD2 family belonging to the immunoglobulin superfamily of receptors. SLAM is a co-stimulatory molecule involving T cell activation and also as a receptor for measles virus [41], a bacterial sensor [42], and responsible for the NKT lineage development [43]. The activation of SLAM has been shown to associate with numerous distinct downstream activities, including augmenting T cell mediated cytotoxicity through a sequence of signaling transduction, including NF-kappa B activation, Stat1 phosphorylation and T-bet induction [44]; increasing recruitment of protein kinase C (PKC)-theta and the activation of NF-kappa B p50, both of which are involved in enhancing T helper 2 cytokines production and natural killer T cell development [45,46].
Two SNPs, rs13049286 and rs3827219 are both located in \textit{RIPK4}. The expression of RIPK4 is well distributed, including the brain, and found to interact with PKC-delta [47]. This gene is important in sensing cellular stress, such as infection, inflammation, cellular differentiation programs and DNA damage. It also mediates downstream signaling, in particular the activation of NF-kappa B and the induction of apoptosis [48].

The identification of \textit{NFKB1}, \textit{RIPK4}, and \textit{SLAMF1} in this study suggests that the NF-kappa B pathway plays an important role in the pathogenesis of TRS. NF-kappa B is also found to be related with schizophrenia since the genetic variants in RELA gene, which encoded the protein RelA as one subunit of NF-kappa B, were reported to be associated with schizophrenia and the patients startle responses in a Japanese population [49]. NF-kappa B is a...
key transcriptional factor in the regulation of the expression of many inflammatory factors, such as cytokines, chemokines, and adhesion molecules [50]. Several studies have demonstrated that schizophrenic patients’ cerebrospinal fluid and plasma had abnormal levels of cytokines [51,52,53], the aberrations were especially more pronounced in TRS [54,55,56]. Song et al. found the elevated level of cytokine in first-episode schizophrenic patients was associated with the activation of NF-kappa B [53]. Thus, these suggest abnormal inflammatory response could lead to TRS. One common variant rs20362691 (-94ins/delATTG) identified from resequencing NFKB1 was found to associate with TRS. This SNP is located in 19 base pairs upstream of a functional kB binding site [57]. The promoter assay showed that the NFKB1 promoter with the -94delATTG allele had a lower promoter activity in SH-SY5Y cells in comparison with the -94insATTG allele. This implies that the -94delATTG allele may result in lower expression of NFKB1. Changes in NFKB1 expression could alter the level of p105 and induce divergent dimeric combinations of NF-kappa B, which might cause disturbances in cytokine regulations, and lead to a failure of antipsychotic treatment. However, the association between the abnormal levels of cytokines and NF-kappa B in patients with TRS remains to be established. Two novel non-synonymous polymorphisms (R231L and R534H) were also identified from resequencing. However, these polymorphisms have extremely low frequency in the Han population and their effects on NFkB1 function remain to be elucidated.

Other genetic loci identified in association with TRS in this study suggests genes involved in neuronal development (DOCK4 [58]). A recent study conducted in the Jewish population also identified a SNP (rs2074127) in DOCK4 associated with schizophrenia [59] however, this SNP is not in LD with the DOCK4 SNPs reported in this study (Supplementary Figure S4). Its role in the development of TRS remains to be elucidated.

We also compared our results with previous genetic studies showing associations with TRS (such as variants in CYP3A4 [60], CYP3A5 [60], DRD3 [60], HTR2A [61], HTR3A [62]), none of the variants or their nearby SNPs had a P value lower than 10^-7 in this study. It implicated that these above genes involving in metabolic enzymes and receptors of antipsychotics were not associated with TRS. Furthermore, we also compared our data with previous GWAS on schizophrenia. We examined the P values of the loci previously reported to be associated with schizophrenia in our data. We also checked the vicinity (200 kb) of the reported loci in our data. Only rs1602565 on chromosome 11 showed nominal association (P=3.17x10^-4) in this study (Supplementary Table S6 and Supplementary Figure S5). These data suggested that the genetic loci identified in this study were specifically associated with TRS.

None of the loci identified in this study reached genome-wide significance, this could due to tour sample size lack the statistical power to detect common variants of susceptibility. However, we focused on TRS within schizophrenia, which may represent a more homogeneous group. An independent TRS group was also not available for replication study. Future replication studies in additional population of TRS are required.

In conclusion, we report the first GWAS on TRS in the Han Chinese population. Our data suggest that the NF-kappa B pathway may play an important role in the pathogenesis of TRS. We have also provided the functional effect of the -94delATTG allele showing the possible mechanism of NFKB1 in TRS. Further studies are required to confirm the association of the risk alleles identified in this study across different populations, to identify the causative genetic variants, and to elucidate the underlying molecular mechanisms, which may help to improve treatments for refractory schizophrenia.

**Materials and Methods**

**Subjects**

This study was approved by the Institute Review Board of Taipei Veterans General Hospital Kaohsiung, Kai-Suan Psychiatric Hospital, Jianan Mental Hospital, Bali Psychiatric Center, Tsy-Huey Mental Hospital, Yuli Veterans Hospital, National Taiwan University Hospital and Academia Sinica. Written informed consent was obtained from all the study participants.

A total of 522 unrelated patients with TRS, including 289 males (55.4%) and 233 females (44.6%), were recruited from Yuli Veterans Hospital, Taipei Veterans General Hospital, Kaohsiung Kai-Suan Psychiatric Hospital, Tsy-Huey Mental Hospital, Jianan Mental Hospital, and Bali Psychiatric Center. DNA samples from additional 273 TRS patients were obtained from National Taiwan University Hospital and were used in joint analysis. In addition, DNA samples from 1982 schizophrenic patients were obtained from Yuli Veterans Hospital, Taipei Veterans General Hospital, and National Health Research Institutes. However, the responses to antipsychotic treatments for 1982 schizophrenic patients were not determined.

All patients were diagnosed according to the criteria of DSM-IV for schizophrenia. TRS was defined using a modified Conley and Kelly’s protocol [28]. Briefly, schizophrenic patients with the following criteria were identified as TRS: No improvement in clinical impression (defined as 3 or more in the global improvement subscale of clinical global impression (CGI-I)) after at least six-week trials of antipsychotic therapy at a dose equal to or higher than the equivalent daily dose of 600 mg of chlorpromazine for typical antipsychotics, or for second-generation antipsychotics (risperidone: 6 mg/day; olanzapine: 20 mg/day; quetiapine: 800 mg/day; ziprasidone: 160 mg/day; amisulpride: 800 mg/day; zotepine: 300 mg/day), as well as for patients who were administered the last-line antipsychotic pharmacotherapy, clozapine (50–300 mg/day). All patients with TRS showed more than 5 years of persistent illness (defined as 4 or more in the severity of illness subscale of clinical global impression (CGI-S)). Informed consent was obtained from all participants. Only the Han-Chinese population, which accounts for 98% of the population in Taiwan, was recruited for this study.

The control (N = 2806) was randomly selected from the Han-Chinese Cell and Genome Bank in Taiwan described previously [63], in which more than 3,300 controls were collected and randomly selected through registry.

**Genotyping and Quality Control**

Genomic DNA was isolated from peripheral blood using PUREGENE DNA purification system (Gentre Systems, Minneapolis, MN). Whole-genome scan was conducted using Affymetrix® Genome-wide Human SNP Array 6.0 (Affymetrix, Santa Clara, CA, USA) on 522 TRS patients and 806 controls and genotyping was performed by National Genotyping Center at Academia Sinica. Genotype calling was determined by Affymetrix Power Tool 1.10.2 (Affymetrix) using default parameters.

Quality control of genotype data was performed by examining several summary statistics. First, individual’s gender was double checked by calculating the ratio of loci with heterozygous calls on the X chromosome; After calculating total successful call rate and the minor allele frequency (MAF) of cases and controls for each SNP, SNPs were excluded if one of the following conditions applied: (1) only one allele appeared in both cases and controls; (2)
the total call rate was less than 98%; (3) the total MAF was less than 5% and the total call rate was less than 99%; (4) significant deviation from Hardy-Weinberg equilibrium in the control group \( (P<10^{-4}) \).

Population stratification
Detection of possible population stratification that might influence association analysis was carried out using principal component analysis (supplementary Methods S1, Supplementary Table S7) with genotype data for 100,000 SNPs located at equally spacing across the human genome. Plink (Supplementary Methods S2) was performed to examine if the subjects were related with each other. Variance inflation factor for genomic control was estimated based on all qualified SNPs (Supplementary Methods S3).

Data Analysis
Genotyping data analysis was carried out by comparing the frequencies of allele and genotype between cases and controls using the following single-point methods: genotype, allele-type, trend test (Cochran-Armitage test), dominant, and recessive models. Empirical \( P \)-values were also obtained with \( 10^5 \) simulations. SNPs with \( P \)-values less than \( 2 \times 10^{-8} \), a cut-off for the multiple-comparison adjusted by Bonferroni correction, were considered to be significantly associated with the traits. SNPs with \( P \)-values between \( 10^{-6} \) and \( 10^{-5} \) were considered to have suggestive significant association. Quantile-quantile (Q-Q) plots were then used to examine \( P \)-value distributions (Supplementary Figure S6).

Multi-point/haplotype analysis was performed using the Haploype Score Test [64] implemented in haplo.stat, a suite of S-PLUS/R routines for the analysis of indirectly measured haplotypes, for regions with more than two SNPs having genetic evidences \( (P\text{-value}<10^{-5}) \). Regions were tested with independent \( 10^6 \) simulations.

Validation and joint analysis
Autosomal SNPs with \( P \)-value \(<10^{-5} \) from GWAS in 522 TRS cases and 806 controls were further validated using MALDI-TOF mass spectrometry (SEQUENOM MassARRAY, Sequenom, San Diego, CA, USA). The SNPs retained after cross-platform validation were then genotyped in the additional 273 TRS cases. Joint analysis was then carried out with all the 795 TRS cases and 806 control.

Direct Sequencing
Selected candidate genes were re-sequenced in a discovery cohort consisted of 94 TRS patients and 94 controls. Exons, 200 bp of exon/intron junctions, and a 2-kb region covering the promoter of the selected genes were sequenced using Applied Biosystems 3730 (CA, USA). Contig assembly and SNP identification were determined using Sequencher 4.5 Demo (Gene Codes Cooperation, Ann Arbor, MI, USA). All PCR products were bi-directionally sequenced.

Plasmid Construction for Luciferase Reporter Assay
To assay for the NFKB1 promoter activity, the NFKB1 promoter encompassing the -94ATTG polymorphism (from -1000 to -1) from patients with homoygous -94ATTGATTG (W) or -94ATTG (D) were first cloned into the pGEM-T Easy vector (Promega, Madison, WI, USA) with the forward primer: 5’-CCCGGGGCTTGAATTGACTGATTGTTTTAAAGCT-3’ and the reverse primer: 5’-CTCGAGGTTCCTGGCTGGAAATTCCCACTGA-3’. Both the W and D fragments were then released from the pGEM-T Easy vector and subcloned into the upstream region of the firefly luciferase gene of the pGL3-basic vector (Promega). All constructs were subjected to sequencing to confirm the orientation and integrity.

Transient Transfection and Luciferase Assay
A total of \( 1 \times 10^5 \) SH-SY5Y cells were seeded in each well of a 24-well plate and transfected with 450 ng of each reporter construct along with 50 ng of pRL-TK vector (Promega) containing the Renilla luciferase gene as an indicator for normalization of transfection efficiency. Transfections were performed by using FuGENE HD (Roche Applied Science, Indianapolis, IN, USA) according to manufacturer’s instructions. Cells were incubated for 24 hours and analyzed for luciferase activity with the Dual-Luciferase Assay System (Promega). Firefly luminescence was normalized to Renilla luminescence and reported as relative luciferase activity. All experiments were performed in triplicate and repeated at least three times.

Supporting Information
Figure S1 Principal component analysis (PCA) plot. The PCA plot shows the first two principal components, estimated by EIGENSTRAT [Price et al. Nature Genetics 38, 904–909 (2006)], which was based on genotype data from 100,000 SNPs with equally spacing across the human genome. No population stratification between the 502 TRS cases (CA, marked as blue circle) and 806 controls (CN, marked as pink cross) was detected \((P>0.05,\) and Fst statistics between populations <0.001). (DOCX)

Figure S2 LD blocks of the clusters showing suggestive significant association. LD \((r^2\) and \(D^2\)) blocks of the clusters on chromosome 1 (A), chromosome 4 (B), chromosome 7(C), and chromosome 21 (D), the validated SNPs with \( P \)-value lower than \( 10^{-5} \) are marked in blue. (DOCX)

Figure S3 Refined regional association plots for the five singleton SNPs with suggestive association. For each of the SNP (A) rs461409, (B) rs123533497, (C) rs9314462, (D) rs9646503, and (E) rs11673496, the \(-\log_{10}P\) values for the trend test from Affymetrix SNP 6.0 Array in 522 cases and 806 controls are plotted as red diamond according to their genomic position (NCBI Build 36.3). The SNPs with the strongest signal are represented as blue diamonds. The recombination rates (right y-axis) based on the Chinese HapMap population is plotted as green lines to reflect the local linkage structure around the significant SNPs. (DOCX)

Figure S4 LD blocks of the DOCK4 SNPs. (DOCX)

Figure S5 Comparisons to previous GWAS. For each of the (A) PTBP2, (B) PLXN4, (C) ZNF804A, (D) FXR1, (E) MHC region/SLC17A1/SLC17A3/BTN2A2/HIST1H2BJ/PRSS16/PM1212/ZNFX1/PGD1, (F) MHC region/NOTCH4/HLA-DQAI, (G) RELN, (H) SMARCAL2, (J) PLAA, (J) ANK3, (K) Intergenic region on 11p14.1, (L) NRGV11 of HEHCAFM, (M) Intergenic region on 16p13.2, (N) AGSM1, (O) TCF7, the \(-\log_{10}P\) values from primary scan are plotted as a function of genomic position (NCBI Build 36). The reported SNPs in previous GWAS are denoted by blue diamonds. Estimated recombination rates (right y-axis) based on the Chinese HapMap population is plotted to reflect the local linkage
dis-equilibrium structure around the significant SNPs. Gene annotations and number of transcripts were taken from NCBI.

**Figure S6** Quantile-quantile (QQ) plots. QQ plot is shown for the trend test. P-values are based on the 694,436SNPs which passed quality filters from 522 cases and 806 controls. The upper and lower boundaries of the 95% confidence bands are represented by the blue lines.

**Table S1** Quality control of the genotyping results. Breakdown of the number (N) of SNPs and samples which passed the QC filter.

**Table S2** Concordance rates for the 19 SNPs with significant associations in the initial GWA analysis.

**Table S3** Multipoint/haplotype analysis of the clusters on chromosome 1 (A), chromosome 4 (B), and chromosome 7 (C).

**Table S4** Testing TRS association results with schizophrenia.

**Table S5** SNPs showing suggestive significant associations adjusted using genomic control.

**Table S6** Previously reported loci and SNPs associated with schizophrenia.

**References**

1. Saha S, Chant D, Welham J, McGrath J (2005) A systematic review of the prevalence of schizophrenia. PLoS Med 2: e141.

2. Chien IC, Chou YJ, Lin CH, Bih SH, Chou P, et al. (2004) Prevalence and incidence of schizophrenia among national health insurance enrollees in Taiwan, 1996–2001. Psychiatry Clin Neurosci 58: 611–618.

3. Hyman SE (2008) A glimmer of light for neuropsychiatric disorders. Nature 455: 890–893.

4. Gottsmann II (1991) Schizophrenia genesis: the origins of madness. New York: Freeman.

5. Cardno AG, Gottsmann II (2000) Twin studies of schizophrenia: from how-and-where concordances to star wars Mx and functional genomics. Am J Med Genet 97: 12–17.

6. Shaikh S, Collier D, Arranz M, Ball D, Gill M, et al. (1994) DRD2 Ser311/Cys311 polymorphism in schizophrenia. Lancet 343: 1045–1046.

7. Inayama Y, Yoneuda H, Sakai T, Ishida T, Nonomura Y, et al. (1996) Positive association between a DNA sequence variant in the serotonin 2A receptor gene and schizophrenia. Am J Med Genet 67: 103–105.

8. Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, et al. (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 70: 713–721.

9. Koga M, Ishiguro H, Yazaki S, Horiuchi Y, Arai M, et al. (2009) Involvement of the SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. Hum Mol Genet 18: 2483–2494.

10. Gerber DJ, Hall D, Miyakawa T, Demars S, Gogos JA, et al. (2003) Evidence for association of schizophrenia with genetic variation in the lgo2.3 gene, PPM1C, encoding the calcineurin gamma subunit. Proc Natl Acad Sci U S A 100: 8993–8998.

11. Crow TJ (2007) How and why genetic linkage has not solved the problem of psychosis: review and hypothesis. Am J Psychiatry 164: 13–21.

12. Sanders AR, Duan J, Levinson DF, Shi J, He D, et al. (2008) No significant association of 14 candidate genes with schizophrenia in a large European ancestry sample: implications for psychiatric genetics. Am J Psychiatry 165: 497–506.

13. O’Donovan MC, Craddock N, Norton N, Williams H, Pruce T, et al. (2008) Identification of loci associated with schizophrenia by genome-wide association and follow-up. Nat Genet 40: 1033–1035.

14. Lencz T, Thielson D, Maher BS, Bigdeli T, Wormley B, et al. (2009) Replication of association between schizophrenia and ZNF804A in the Irish Case-Control Study of Schizophrenia sample. Mol Psychiatry 15: 29–37.

15. Riley B, Thiselton D, Maher BS, Gogos JA, et al. (2009) Common variants on chromosome 6p22.1 are associated with schizophrenia. Nature 460: 753–757.

16. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, et al. (2009) Common variants conferring risk of schizophrenia. Nature 460: 744–747.

17. Hattori K, Mattingal M, Kaldor JK, Brown A, Gustafsson O, et al. (2010) Gene variants associated with schizophrenia in a Norwegian genome-wide study are replicated in a large European cohort. J Psychiatr Res 44: 748–753.

18. Purcell SM, Roy NK, Stone JL, Visscher PM, O’Donovan MC, et al. (2007) Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 460: 748–750.

19. Crow TJ (2007) How and why genetic linkage has not solved the problem of psychosis: review and hypothesis. Am J Psychiatry 164: 13–21.

20. Shifman S, Johannesson M, Bronstein M, Chen SX, Collier DA, et al. (2008) Genome-wide association identifies a common variant in the reelin receptor gene which increases the risk of schizophrenia only in women. PLoS Genet 4: e28.

21. Koga M, Ishiguro H, Yazaki S, Horiiuchi Y, Arai M, et al. (2009) Involvement of SMARCA2/BRM in the SWI/SNF chromatin-remodeling complex in schizophrenia. Hum Mol Genet 18: 2483–2494.

22. Conley RR, Kelly DL (2001) Management of treatment resistance in schizophrenia. Biol Psychiatry 50: 898–911.

**Table S7** Adjustment of the top SNPs for drinking and inclusion of 20 principal components as covariates in logistic regression.

**Methods S1** Principal component analysis using EIGEN-STRAT.

**Methods S2** Analyses based on pair-wise identity-by-state (IBS) distance using Plink.

**Methods S3** Genomic Control.

**Acknowledgments**

We thank all the patients who participated in this study. We gratefully acknowledge the National Clinical Core for Genomic Medicine at Academia Sinica and the National Genotyping Core for providing supports of subject recruitment, genotyping performance, and the statistical analysis.

**Author Contributions**

Conceived and designed the experiments: YJL, HHW MTML, YTC, CJH. Performed the experiments: YJL, HHW MTML, YTC, CJH. Contributed reagents/materials/analysis tools: SCH, CCC CHL, MSC, CCK, DKL, CKW, CML, YLL, HGH, ICL, SJT, Chia-Hsiang Chen, HFL C. JH. Wrote the paper: YJL, HHW, MTML, JYW.
29. Ellek H (2007) Treatment-resistant schizophrenia. Psychiatr Clin North Am 30: 511–533.
30. van Kammen DP, Schooler N (1990) Are biochemical markers for treatment-resistant schizophrenia state dependent or traits? Clin Neuropharmacol 13 Suppl 1: S16–28.
31. Böder RM, Wu H, Chakos MH, Bogerts B, Pollack S, et al. (1994) Cerebral morphometry and dopamine treatment in schizophrenia. J Clin Psychiatry 55 Suppl B: 53–56.
32. Stern RG, Kohan RS, Davidson M (1993) Predictors of response to neuroleptic treatment in schizophrenia. Psychiatr Clin North Am 16: 313–338.
33. Lee M, Jayathilake K, Dai J, Melzner H (2010) Decreased plasma tryptophan and tryptophan/natural amino acid ratio in patients with neuroleptic-resistant schizophrenia: Relationship to plasma cortisol concentration. Psychiatry Res.
34. Karban AS, Okazaki T, Panhuyzen CI, Gallegos T, Potter JJ, et al. (2004) Functional annotation of a novel NFκB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13: 35–45.
35. Lin L, DeMartino GN, Greene WC (1998) Cotranslational biogenesis of NF-kappaB p50 by the 26S proteasome. Cell 92: 819–828.
36. Rice NR, MacKichan ML, Israel A (1992) The precursor of NF-kappaB p50 has I kappa B-like functions. Cell 71: 243–253.
37. Shihodha S, Aggarwal BB (2004) Nuclear factor-kappaB: a friend or a foe in cancer? Biochem Pharmacol 68: 1071–1080.
38. Zhong H, May MJ, Jimi E, Ghosh S (2002) The phosphorylation status of nuclear NF-kappaB determines its association with CBP/p300 or HDAC-1. Mol Cell 9: 625–636.
39. Chen F, Castranova V, Shi X, Demers LM (1999) New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 45: 7–17.
40. Tatsuo H, Ono N, Tanaka K, Yanagi Y (2000) SLAM (CDw150) is a cellular protein kinase that interacts with protein kinase Cdelta. Cloning, characterization, and gene analysis. J Biol Chem 275: 36350–36357.
41. Meylan E, Tschopp J (2003) The RIP kinases: crucial integrators of cellular stress. Trends Biochem Sci 30: 151–159.
42. Hashimoto R, Ohl K, Yasuda Y, Fukumoto M, Yamamori H, et al. (2011) Variants of the RELA gene are associated with schizophrenia and their startle responses. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 36: 1921–1931.
43. Barnes PJ, Karim M (1997) Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336: 1066–1071.
44. Katila H, Appelberg B, Hurme M, Rimon R (1994) Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr Res 12: 29–34.
45. Porvin S, Stip E, Sepeluy AA, Grendon A, Bah R, et al. (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63: 801–808.
46. Song XQ, Le LX, Li WQ, Hao YH, Zhao JP (2009) The interaction of nuclear factor-kappaB and cytokines is associated with schizophrenia. Biol Psychiatry 65: 401–408.
47. Lin A, Kushi G, Bigotti S, Tura GJ, De Jong R, et al. (1998) The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 22: 9–15.
48. Mars M, Bocchio Chiavetto L, Bigotti S, Battista Tura G, Pioli R, et al. (2000) Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 10: 119–124.
49. Mars M, Bocchio Chiavetto L, Bigotti S, Battista Tura GJ, Pioli R, et al. (2002) Increased serum interleukin-6 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 54: 291–294.
50. Ten RM, Paya CV, Izael N, Le Bail O, Mattei MG, et al. (1992) The characterization of the promoter of the gene encoding the p50 subunit of NF-kappaB indicates that it participates in its own regulation. Embryol J 11: 195–203.
51. Ueda S, Fujimoto S, Hirono K, Negishi M, Kato H (2000) Dock5 regulates dendritic development in hippocampal neurons. J Neurosci Res 68: 3052–3061.
52. Alkelai A, Lugoli S, Greenbaum L, Kohin Y, Kanyas-Sarner K, et al. (2011) DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. pp 1–11.
53. Kohlrausch FB, Gama CS, Lobato MI, Belmonte-de-Abreu P, Callegari-Jacques SM, et al. (2008) Naturalistic pharmacogenomic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. Pharmacogenetics Genomics 18: 599–609.
54. Joober R, Benkelfat C, Brieseboi K, Toulouse A, Turecki G, et al. (2008) Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. J Psychiatry Neurosci 33: 141–146.
55. Joober R, Benkelfat C, Brieseboi K, Toulouse A, Turecki G, et al. (1999) T102C polymorphism in the 5HT2A gene and schizophrenia: relation to phenotype and drug response variability. J Psychiatry Neurosci 24: 141–146.
56. Ji X, Takahashi N, Saito S, Ishihara R, Maeno N, et al. (2008) Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and drug response variability. J Psychiatry Neurosci 24: 141–146.
57. Pan WH, Fan CS, Wu JY, Hung YT, Ho MS, et al. (2006) Han Chinese cell and genome bank in Taiwan: purpose, design and ethical considerations. Hum Hered 61: 27–30.
58. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA (2002) Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 70: 425–434.
59. Ishihara R, Maeno N, Takahashi N, Saito S, Ishihara R, et al. (2008) Relationship between three serotonin receptor subtypes (HTR3A, HTR2A and HTR4) and treatment-resistant schizophrenia in the Japanese population. Neurosci Lett 435: 95–98.
60. Joober R, Benkelfat C, Brieseboi K, Toulouse A, Turecki G, et al. (2008) Naturalistic pharmacogenetic study of treatment resistance to typical neuroleptics in European-Brazilian schizophrenics. J Psychiatry Neurosci 24: 141–146.
61. Katila H, Appelberg B, Hurme M, Rimon R (1994) Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr Res 12: 29–34.
62. Porvin S, Stip E, Sepeluy AA, Grendon A, Bah R, et al. (2008) Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 63: 801–808.
63. Song XQ, Le LX, Li WQ, Hao YH, Zhao JP (2009) The interaction of nuclear factor-kappaB and cytokines is associated with schizophrenia. Biol Psychiatry 65: 401–408.
64. Lin A, Kushi G, Bigotti S, Tura GJ, De Jong R, et al. (1998) The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr Res 22: 9–15.
65. Mars M, Bocchio Chiavetto L, Bigotti S, Battista Tura G, Pioli R, et al. (2000) Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics. Eur Neuropsychopharmacol 10: 119–124.
66. Mars M, Bocchio Chiavetto L, Bigotti S, Battista Tura GJ, Pioli R, et al. (2002) Increased serum interleukin-6 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor. Schizophr Res 54: 291–294.
67. Ten RM, Paya CV, Izael N, Le Bail O, Mattei MG, et al. (1992) The characterization of the promoter of the gene encoding the p50 subunit of NF-kappaB indicates that it participates in its own regulation. Embryol J 11: 195–203.
68. Ueda S, Fujimoto S, Hirono K, Negishi M, Kato H (2000) Dock5 regulates dendritic development in hippocampal neurons. J Neurosci Res 68: 3052–3061.
69. Alkelai A, Lugoli S, Greenbaum L, Kohin Y, Kanyas-Sarner K, et al. (2011) DOCK4 and CEACAM21 as novel schizophrenia candidate genes in the Jewish population. The international journal of neuropsychopharmacology/official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. pp 1–11.